Literature DB >> 28187282

Implementing Genome-Driven Oncology.

David M Hyman1, Barry S Taylor2, José Baselga3.   

Abstract

Early successes in identifying and targeting individual oncogenic drivers, together with the increasing feasibility of sequencing tumor genomes, have brought forth the promise of genome-driven oncology care. As we expand the breadth and depth of genomic analyses, the biological and clinical complexity of its implementation will be unparalleled. Challenges include target credentialing and validation, implementing drug combinations, clinical trial designs, targeting tumor heterogeneity, and deploying technologies beyond DNA sequencing, among others. We review how contemporary approaches are tackling these challenges and will ultimately serve as an engine for biological discovery and increase our insight into cancer and its treatment.
Copyright © 2017. Published by Elsevier Inc.

Entities:  

Keywords:  Precision medicine; basket studies; genome-driven oncology; next-generation sequencing; targeted therapy

Mesh:

Year:  2017        PMID: 28187282      PMCID: PMC5463457          DOI: 10.1016/j.cell.2016.12.015

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  94 in total

1.  Improved overall survival in melanoma with combined dabrafenib and trametinib.

Authors:  Caroline Robert; Boguslawa Karaszewska; Jacob Schachter; Piotr Rutkowski; Andrzej Mackiewicz; Daniil Stroiakovski; Michael Lichinitser; Reinhard Dummer; Florent Grange; Laurent Mortier; Vanna Chiarion-Sileni; Kamil Drucis; Ivana Krajsova; Axel Hauschild; Paul Lorigan; Pascal Wolter; Georgina V Long; Keith Flaherty; Paul Nathan; Antoni Ribas; Anne-Marie Martin; Peng Sun; Wendy Crist; Jeff Legos; Stephen D Rubin; Shonda M Little; Dirk Schadendorf
Journal:  N Engl J Med       Date:  2014-11-16       Impact factor: 91.245

2.  Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.

Authors:  José Baselga; Mario Campone; Martine Piccart; Howard A Burris; Hope S Rugo; Tarek Sahmoud; Shinzaburo Noguchi; Michael Gnant; Kathleen I Pritchard; Fabienne Lebrun; J Thaddeus Beck; Yoshinori Ito; Denise Yardley; Ines Deleu; Alejandra Perez; Thomas Bachelot; Luc Vittori; Zhiying Xu; Pabak Mukhopadhyay; David Lebwohl; Gabriel N Hortobagyi
Journal:  N Engl J Med       Date:  2011-12-07       Impact factor: 91.245

3.  Counting absolute numbers of molecules using unique molecular identifiers.

Authors:  Teemu Kivioja; Anna Vähärautio; Kasper Karlsson; Martin Bonke; Martin Enge; Sten Linnarsson; Jussi Taipale
Journal:  Nat Methods       Date:  2011-11-20       Impact factor: 28.547

4.  Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial.

Authors:  Marcia S Brose; Maria E Cabanillas; Ezra E W Cohen; Lori J Wirth; Todd Riehl; Huibin Yue; Steven I Sherman; Eric J Sherman
Journal:  Lancet Oncol       Date:  2016-07-23       Impact factor: 41.316

5.  Toward a Shared Vision for Cancer Genomic Data.

Authors:  Robert L Grossman; Allison P Heath; Vincent Ferretti; Harold E Varmus; Douglas R Lowy; Warren A Kibbe; Louis M Staudt
Journal:  N Engl J Med       Date:  2016-09-22       Impact factor: 91.245

6.  Molecular determinants of resistance to antiandrogen therapy.

Authors:  Charlie D Chen; Derek S Welsbie; Chris Tran; Sung Hee Baek; Randy Chen; Robert Vessella; Michael G Rosenfeld; Charles L Sawyers
Journal:  Nat Med       Date:  2003-12-21       Impact factor: 53.440

7.  Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.

Authors:  Giuseppe Saglio; Dong-Wook Kim; Surapol Issaragrisil; Philipp le Coutre; Gabriel Etienne; Clarisse Lobo; Ricardo Pasquini; Richard E Clark; Andreas Hochhaus; Timothy P Hughes; Neil Gallagher; Albert Hoenekopp; Mei Dong; Ariful Haque; Richard A Larson; Hagop M Kantarjian
Journal:  N Engl J Med       Date:  2010-06-05       Impact factor: 91.245

8.  RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E).

Authors:  Poulikos I Poulikakos; Yogindra Persaud; Manickam Janakiraman; Xiangju Kong; Charles Ng; Gatien Moriceau; Hubing Shi; Mohammad Atefi; Bjoern Titz; May Tal Gabay; Maayan Salton; Kimberly B Dahlman; Madhavi Tadi; Jennifer A Wargo; Keith T Flaherty; Mark C Kelley; Tom Misteli; Paul B Chapman; Jeffrey A Sosman; Thomas G Graeber; Antoni Ribas; Roger S Lo; Neal Rosen; David B Solit
Journal:  Nature       Date:  2011-11-23       Impact factor: 49.962

9.  Randomised proof-of-concept phase II trial comparing targeted therapy based on tumour molecular profiling vs conventional therapy in patients with refractory cancer: results of the feasibility part of the SHIVA trial.

Authors:  C Le Tourneau; X Paoletti; N Servant; I Bièche; D Gentien; T Rio Frio; A Vincent-Salomon; V Servois; J Romejon; O Mariani; V Bernard; P Huppe; G Pierron; F Mulot; C Callens; J Wong; C Mauborgne; E Rouleau; C Reyes; E Henry; Q Leroy; P Gestraud; P La Rosa; L Escalup; E Mitry; O Trédan; J-P Delord; M Campone; A Goncalves; N Isambert; C Gavoille; M Kamal
Journal:  Br J Cancer       Date:  2014-04-24       Impact factor: 7.640

10.  Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer.

Authors:  Colin C Pritchard; Joaquin Mateo; Michael F Walsh; Navonil De Sarkar; Wassim Abida; Himisha Beltran; Andrea Garofalo; Roman Gulati; Suzanne Carreira; Rosalind Eeles; Olivier Elemento; Mark A Rubin; Dan Robinson; Robert Lonigro; Maha Hussain; Arul Chinnaiyan; Jake Vinson; Julie Filipenko; Levi Garraway; Mary-Ellen Taplin; Saud AlDubayan; G Celine Han; Mallory Beightol; Colm Morrissey; Belinda Nghiem; Heather H Cheng; Bruce Montgomery; Tom Walsh; Silvia Casadei; Michael Berger; Liying Zhang; Ahmet Zehir; Joseph Vijai; Howard I Scher; Charles Sawyers; Nikolaus Schultz; Philip W Kantoff; David Solit; Mark Robson; Eliezer M Van Allen; Kenneth Offit; Johann de Bono; Peter S Nelson
Journal:  N Engl J Med       Date:  2016-07-06       Impact factor: 91.245

View more
  155 in total

1.  Widespread Selection for Oncogenic Mutant Allele Imbalance in Cancer.

Authors:  Craig M Bielski; Mark T A Donoghue; Mayur Gadiya; Aphrothiti J Hanrahan; Helen H Won; Matthew T Chang; Philip Jonsson; Alexander V Penson; Alexander Gorelick; Christopher Harris; Alison M Schram; Aijazuddin Syed; Ahmet Zehir; Paul B Chapman; David M Hyman; David B Solit; Kevin Shannon; Sarat Chandarlapaty; Michael F Berger; Barry S Taylor
Journal:  Cancer Cell       Date:  2018-11-01       Impact factor: 31.743

2.  Functional Proteomics and Deep Network Interrogation Reveal a Complex Mechanism of Action of Midostaurin in Lung Cancer Cells.

Authors:  Claudia Ctortecka; Vinayak Palve; Brent M Kuenzi; Bin Fang; Natalia J Sumi; Victoria Izumi; Silvia Novakova; Fumi Kinose; Lily L Remsing Rix; Eric B Haura; John Matthew Koomen; Uwe Rix
Journal:  Mol Cell Proteomics       Date:  2018-09-14       Impact factor: 5.911

3.  Feasibility of endobronchial ultrasound transbronchial needle aspiration for massively parallel next-generation sequencing in thoracic cancer patients.

Authors:  Simon R Turner; Darren Buonocore; Patrice Desmeules; Natasha Rekhtman; Snjezana Dogan; Oscar Lin; Maria E Arcila; David R Jones; James Huang
Journal:  Lung Cancer       Date:  2018-03-07       Impact factor: 5.705

4.  TRK Fusions Are Enriched in Cancers with Uncommon Histologies and the Absence of Canonical Driver Mutations.

Authors:  Ezra Y Rosen; Debra A Goldman; Jaclyn F Hechtman; Ryma Benayed; Alison M Schram; Emiliano Cocco; Sophie Shifman; Yixiao Gong; Ritika Kundra; James P Solomon; Alberto Bardelli; Maurizio Scaltriti; Alexander Drilon; Alexia Iasonos; Barry S Taylor; David M Hyman
Journal:  Clin Cancer Res       Date:  2019-12-23       Impact factor: 12.531

5.  Multiplexed drug testing of tumor slices using a microfluidic platform.

Authors:  A Folch; R C Rostomily; L F Horowitz; A D Rodriguez; Z Dereli-Korkut; R Lin; K Castro; A M Mikheev; R J Monnat
Journal:  NPJ Precis Oncol       Date:  2020-05-19

Review 6.  Clinical potential of mass spectrometry-based proteogenomics.

Authors:  Bing Zhang; Jeffrey R Whiteaker; Andrew N Hoofnagle; Geoffrey S Baird; Karin D Rodland; Amanda G Paulovich
Journal:  Nat Rev Clin Oncol       Date:  2019-04       Impact factor: 66.675

Review 7.  Tackling tumor heterogeneity and phenotypic plasticity in cancer precision medicine: our experience and a literature review.

Authors:  Shijie Sheng; M Margarida Bernardo; Sijana H Dzinic; Kang Chen; Elisabeth I Heath; Wael A Sakr
Journal:  Cancer Metastasis Rev       Date:  2018-12       Impact factor: 9.264

Review 8.  Personalized Cancer Models for Target Discovery and Precision Medicine.

Authors:  Carla Grandori; Christopher J Kemp
Journal:  Trends Cancer       Date:  2018-08-08

9.  Proteogenomic Landscape of Breast Cancer Tumorigenesis and Targeted Therapy.

Authors:  Karsten Krug; Eric J Jaehnig; Shankha Satpathy; Lili Blumenberg; Alla Karpova; Meenakshi Anurag; George Miles; Philipp Mertins; Yifat Geffen; Lauren C Tang; David I Heiman; Song Cao; Yosef E Maruvka; Jonathan T Lei; Chen Huang; Ramani B Kothadia; Antonio Colaprico; Chet Birger; Jarey Wang; Yongchao Dou; Bo Wen; Zhiao Shi; Yuxing Liao; Maciej Wiznerowicz; Matthew A Wyczalkowski; Xi Steven Chen; Jacob J Kennedy; Amanda G Paulovich; Mathangi Thiagarajan; Christopher R Kinsinger; Tara Hiltke; Emily S Boja; Mehdi Mesri; Ana I Robles; Henry Rodriguez; Thomas F Westbrook; Li Ding; Gad Getz; Karl R Clauser; David Fenyö; Kelly V Ruggles; Bing Zhang; D R Mani; Steven A Carr; Matthew J Ellis; Michael A Gillette
Journal:  Cell       Date:  2020-11-18       Impact factor: 41.582

Review 10.  [Status of the availability and use of next generation sequencing (NGS) in bladder cancer-a questionnaire within the uropathology working group].

Authors:  N Ortiz-Brüchle; M Muders; M Toma; I Esposito; A Hartmann; R Stöhr; H Reis; P Wild; J Köllermann; F Bremmer; J Leichsenring; A Stenzinger; S Merkelbach-Bruse; S Kirfel; S Perner; N Hartmann; W Roth; A Jung; T Kirchner; K Schwamborn; N Pfarr; E Dahl; R Knüchel; N T Gaisa
Journal:  Urologe A       Date:  2020-03       Impact factor: 0.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.